Surmodics, Inc. (SRDX)

NASDAQ: SRDX · IEX Real-Time Price · USD
34.22
-1.05 (-2.98%)
May 23, 2024, 4:00 PM EDT - Market closed
-2.98%
Market Cap 487.98M
Revenue (ttm) 142.96M
Net Income (ttm) 13.50M
Shares Out 14.26M
EPS (ttm) 0.96
PE Ratio 35.65
Forward PE 81.97
Dividend n/a
Ex-Dividend Date n/a
Volume 28,763
Open 35.22
Previous Close 35.27
Day's Range 33.95 - 35.36
52-Week Range 16.79 - 39.41
Beta 1.04
Analysts Strong Buy
Price Target 57.00 (+66.57%)
Earnings Date May 1, 2024

About SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Mar 4, 1998
Employees 376
Stock Exchange NASDAQ
Ticker Symbol SRDX
Full Company Profile

Financial Performance

In 2023, Surmodics's revenue was $132.58 million, an increase of 32.65% compared to the previous year's $99.95 million. Losses were -$1.54 million, -94.37% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SRDX stock is "Strong Buy." The 12-month stock price forecast is $57.0, which is an increase of 66.57% from the latest price.

Price Target
$57.0
(66.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today report...

23 days ago - Business Wire

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announ...

5 weeks ago - Business Wire

Surmodics to Participate in Upcoming Investor Conferences in March and April

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...

3 months ago - Business Wire

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...

4 months ago - Business Wire

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the co...

4 months ago - Business Wire

Surmodics to Host Virtual Annual Meeting of Shareholders

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting...

4 months ago - Business Wire

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first q...

4 months ago - Business Wire

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...

6 months ago - Business Wire

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-mont...

6 months ago - Business Wire

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem...

6 months ago - Business Wire

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...

7 months ago - Business Wire

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Profess...

7 months ago - Business Wire

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-mont...

7 months ago - Business Wire

Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical...

7 months ago - Business Wire

Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that fourth ...

8 months ago - Business Wire

Surmodics to Participate in Upcoming Investor Conferences in August

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will participate in upcoming investor conferences.

10 months ago - Business Wire

Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...

10 months ago - Business Wire

Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #August22023--Surmodics, Inc. (SRDX) announces third quarter of fiscal year 2023 financial results will be released on Wednesday, August 2.

11 months ago - Business Wire

Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Angioplasty--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announc...

1 year ago - Business Wire

Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #AcuteLimbIschemia--Surmodics announced it has received FDA 510(k) clearance for its Pounce™ LP (Low Profile) Thrombectomy System, a new addition to the Pounce p...

1 year ago - Business Wire

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CHRSICPTYS
1 year ago - Benzinga

Surmodics to Participate in the Jefferies Healthcare Conference on June 8

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #JefferiesHealthcareConference--Surmodics today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, at 1:30 p.m. E...

1 year ago - Business Wire

Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #ConferenceCall--Surmodics today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year 2...

1 year ago - Business Wire

Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #MedicalDevice--The PROWL registry will collect real-world efficacy and safety outcomes data for endovascular interventions using the Pounce thrombectomy system.

1 year ago - Business Wire

Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #ConferenceCall--Surmodics announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26.

1 year ago - Business Wire